clinical trial · NCT07424404
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
Karuna Therapeutics, Inc., a Bristol Myers Squibb company·phase3·recruiting·n = 400
SchizophreniaAutism-Related IrritabilityKarXT
brief summary
The purpose of this study is to evaluate the long-term safety and tolerability of KarXT and KarX-EC for the treatment of Schizophrenia and autism-related irritability in adolescents, respectively
started
Apr 7, 2026
primary completion
Mar 8, 2030
completion
Mar 8, 2030
last updated
May 11, 2026
official title
A Phase 3 Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of KarXT in Adolescents (13 to 17 Years of Age) With Schizophrenia and KarXT+KarX-EC in Children and Adolescents (5 to 17 Years of Age) With Irritability Associated With Autism Spectrum Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol